<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250603</date><key>collection.key</key><document><id>PMC6449948</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.1186/s12885-019-5516-5</infon><infon key="article-id_pmc">PMC6449948</infon><infon key="article-id_pmid">30947706</infon><infon key="article-id_publisher-id">5516</infon><infon key="elocation-id">315</infon><infon key="kwd">Newcastle disease virus AF2240 Breast cancer 4 T1 cells Cytokines</infon><infon key="license">Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</infon><infon key="name_0">surname:Raihan;given-names:Juraimi</infon><infon key="name_1">surname:Ahmad;given-names:Umar</infon><infon key="name_2">surname:Yong;given-names:Yoke Keong</infon><infon key="name_3">surname:Eshak;given-names:Zolkapli</infon><infon key="name_4">surname:Othman;given-names:Fauziah</infon><infon key="name_5">surname:Ideris;given-names:Aini</infon><infon key="section_type">TITLE</infon><infon key="title">Keywords</infon><infon key="type">front</infon><infon key="volume">19</infon><infon key="year">2019</infon><offset>0</offset><text>Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>131</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>142</offset><text>Different strains of Newcastle disease virus (NDV) worldwide proved to have tumouricidal activity in several types of cancer cells. However, the possible anti-cancer activity of Malaysian NDV AF2240 strain and its mechanism of action remains unknown. The ability of cytokine-related apoptosis-inducing NDV AF2240 to treat breast cancer was investigated in the current study.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>517</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>525</offset><text>A total of 90 mice were used and divided into 15 groups, each group comprising of 6 mice. Tumour, body weight and mortality of the mice were determined throughout the experiment, to observe the effect of NDV and NDV + tamoxifen treatments on the mice. In addition, the toxic effect of the treatments was determined through liver function test. In order to elucidate the involvement of cytokine production induced by NDV, a total of six cytokines, i.e. IL-6, IFN-gamma, MCP-1, IL-10, IL12p70 and TNF-alpha were measured using cytometric bead array assay (plasma) and enzyme-linked immunosorbent spot (isolated splenocytes).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1148</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1156</offset><text>The results demonstrated that 4 T1 breast cancer cells in allotransplanted mice treated with AF2240 showed a noticeable inhibition of tumour growth and induce apoptotic-related cytokines.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1346</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1358</offset><text>NDV AF2240 suppression of breast tumour growth is associated with induction of apoptotic-related cytokines. It would be important to further investigate the molecular mechanism underlaying cytokines production by Newcastle disease virus.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1598</offset><text>Electronic supplementary material</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1632</offset><text>The online version of this article (10.1186/s12885-019-5516-5) contains supplementary material, which is available to authorized users.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1768</offset><text>Background</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1779</offset><text>To date, cancer remains the tenth leading causes of death worldwide. According to National Cancer Registry Report 2007, breast cancer is the top ranking malignancy that affects Malaysians followed by colorectal cancer. There are a total of 3292 new cases reported in the year 2007 and contributed 18.1% out of all the types of cancers in Malaysia. However, the number of new cases are slightly less compared with the cases in 2003 (3738 cases reported) and the patient survival rate has also improved. This could be as a result of sensitization campaign, which increases awareness and educates citizen. In addition, early detection, development of advanced medical instruments and surgical techniques, and discovery of various new and effective anti-cancer agents may have resulted in the reduction in the number of cases.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2602</offset><text>There are various types of treatments available for breast cancer patients, including surgery, radiotherapy and chemotherapy. Also, numerous anti-cancer drugs, such as tamoxifen, trastuzumab and bevacizumab, have been in the market since their discoveries. However, these drugs show many side effects. For instance, anastrozole that is used for the treatment of breast cancer patients after surgery leads to severe memory impairment and long term use of tamoxifen increases the risk of endometrial cancer. Due to this, tremendous efforts have been made by scientists around the world to explore and develop targeted drug systems with least or no side effects that will specifically target cancer cells without affecting normal healthy cells.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3344</offset><text>Recently, the trend of manipulating a virus to serve as an anti-cancer agent has been increasing. Among all types of viruses, oncolytic virus specifically targets cancer cell without causing excessive damage to non-cancerous cells. Numerous oncolytic viruses from different family exhibit different mechanism of tumour selectivity. For instance, herpes simplex virus mutant, G207 from herpesviridae family has been used for the treatment of malignant glioma. Mumps virus from the family of paramyxoviridae has been previously used against ovarian cancer, and Sindbis virus from togaviridae family has been proposed as a therapy for cervical and ovarian cancers.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4006</offset><text>Apart from all these viruses, oncolytic Newcastle disease virus (NDV) also has potential as an anti-cancer agent because of its inability to induce immune escape mechanism in mammalian cells. Thus, it may be suitable as an immunologic adjuvant in a human cancer vaccine. NDV belongs to paramyxoviridae family, and causes inflammation of respiratory tract, brain and gastrointestinal tract to poultry. However, it only causes mild flu-like symptoms and conjunctivitis in human. While in mouse it is reported to stimulate production of type I interferon response upon infection and resistance of both normal and neoplastic cells to virus replication. The most common strain that is found in Malaysia is NDV AF2440. It has been reported that NDV AF2240 was capable of stimulating apoptosis in breast cancer cells and the apoptotic effects were correlated with the production of pro-inflammatory cytokines in the tumour cells. These effects are the first steps of immunotherapeutic effects of many crucial cytokines that help in combating breast tumour cells. Several strains of NDV such as 73-T, HUJ, PV701 (MK107), MTH68, and Ulster have been shown to exhibit similar oncolytic properties as that of NDV AF2240 strain. Furthermore, additional exploration of the three Malaysian oncolytic NDV strains, AF2240, F and V4, have also been studied on different types of cancer cell lines in both in vivo and in vitro screening. Of all these strains, only AF2240 (velogenic) was found to be more effective and showed better cytotoxic effect on in vitro MCF-7 cells as compared to the V4-UPM (lentogenic) strain. Thus, AF2240 strain has the most significant anti-cancer activity and had proven to be relatively effective in suppressing tumour growth through apoptosis induction. Given this, here, we investigated the possible apoptotic mechanism of NDV AF2240 against 4 T1 breast cancer cells through cytokines induction.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5920</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5928</offset><text>Incubation of embryonated eggs</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5959</offset><text>Propagation of NDV virus was performed based on the method reported by Blaskovis and Styk. Embryonated chicken eggs aged 9 to 10 days were obtained from Linggi Poultry Farm, Negeri Sembilan, Malaysia. Upon arrival, the eggs were sprayed with 70% ethanol and wiped thoroughly with tissue paper to prevent contamination. The eggs were then kept in a 37  C-humidified incubator for 24 h. The embryos were candled daily to monitor its viability. Same method was also used to determine the margin of air sac of the embryos, which were marked with a pencil prior to inoculation of the virus. All procedures were carried out under biological safety cabinet to minimize any contamination.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6647</offset><text>Virus source and seed virus dilution</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6684</offset><text>The velogenic viscerotropic NDV strain AF2240 was isolated from a local outbreak in the late 1960s and was obtained from Institute of Bioscience of the Universiti Putra Malaysia. Preparation of seed virus depends on the number of eggs used. Briefly, 10-fold of virus dilutions were prepared. First, three centrifuge tubes were filled with 9 ml of phosphate buffer saline (PBS) and the subsequent tubes were filled with 27 ml PBS. Approximately 1 ml of virus was filtered using 0.45 muM filter and added to the first centrifuge tube containing 9 ml PBS and suspended for several times to get 1 in 10 dilutions of the virus. By using a syringe, approximately 1 ml of the dilution was transferred to the second centrifuge tube before being suspended several times. This process was repeated until the third centrifuge tube. Finally, 3 ml of dilution from the third centrifuge tube was transferred to the fourth centrifuge tube containing 27 ml PBS to obtain a dilution of 10- 4 NDV AF2240 which was used for the inoculation of virus in the embryonated chicken eggs.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7767</offset><text>Virus inoculation</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7785</offset><text>Virus was inoculated in the eggs as per the method used by Alexander with slight modification. A small hole approximately 1 mm in diameter was made using a sterile needle right above the air sac margin. By using a syringe, 0.1 ml of virus dilution was inoculated into each egg. Then the eggs were sterilized using 70% ethanol before using melted candle or sterile tape to seal the hole. The eggs were then kept inside the incubator and checked for dead embryos using candling after 48 h. The eggs, which found to have dead embryos were removed and kept in the refrigerator at 4  C. The eggs were monitored daily for 96 h or until 90% of the embryos died. All the eggs were kept in the refrigerator overnight to ensure that the blood vessel is constricted before virus harvesting process. This can avoid collection of blood during harvesting of the allantoic fluid.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8664</offset><text>Virus harvesting</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8681</offset><text>The eggs were left under a biological safety cabinet at room temperature for 30 min to avoid excessive condensation on the shells once removed from the refrigerator. The eggs shells above the air sac were then removed and the membranes were punctured to collect the allantoic fluid. If there were any visible contamination, the eggs were immediately rejected. To confirm the presence of NDV in the allantoic fluid, a rapid test using chicken red blood cells was conducted. The allantoic fluids collected were kept in sterile tubes. Immediately after all the allantoic fluids were harvested, the clarification and purification of the virus was carried out.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9339</offset><text>Virus clarification and purification</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9376</offset><text>In brief, the clarification of allantoic fluid was done at 6000 g, 4  C for 10 min by using a refrigerated centrifuge. The supernatants were then centrifuged at 20,000 rpm, 4  C for 3 h. Again, the supernatant was discarded while the pellet was re-suspended and dissolved in 1 ml NTE buffer (NaCl, Tris-HCl, EDTA, pH 8.0). In addition, 30, 40, 50 and 60% of sucrose gradients were prepared in ultra-clear tubes and kept overnight at 4  C. A few drops of virus in NTE buffer were added to the sucrose solution by using a sterile pipette until all the tubes were equally balanced. The tubes were then centrifuged at 38,000 rpm, 4  C for 4 h by using pre-cooled SW41 rotor (Beckman Coulter, USA). After the centrifugation, observation and marking of the purified band of virus was made under inverted microscope. The band was collected and transferred into polyalomer tubes. The tubes were topped-up with NTE buffer and balanced before subjected to centrifugation at 20,000 rpm at 4  C for 2 h. The pellets obtained were dissolved in 1 ml NTE buffer and filtered using 0.4 mum filter. Finally, the suspensions were kept at -80  C until further use.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10564</offset><text>Preparation of chicken red blood cells for virus titration</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10623</offset><text>Blood was withdrawn from the jugular vein of chicken by using syringe that filled with a mixture of PBS and EDTA to prevent the blood from clotting. The blood was transferred into 15 ml tube and topped-up with PBS, then centrifuged at 1000 rpm at room temperature for 10 min. The supernatant was discarded and the red blood cells were re-suspended in PBS and centrifuged again. This process was repeated for 3 more times. For virus titration purpose, 50 mul of the RBC was diluted in 100 ml PBS to get 0.5% suspension of RBC cell in PBS.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>11171</offset><text>Haemagglutination (HA) test</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11199</offset><text>For HA test, 2nd to 24th well of 96-well plate were filled up with 50 mul of PBS while the 1st well was filled up with 100 mul of purified virus. 50 mul of purified virus was transferred from the 1st well into the 2nd well to make a two-fold dilution and this continued until the 23rd well. Then, 50 mul of the 0.5% RBC suspension was added into all wells and left for 30 min at room temperature. The 1st well was served as positive control whereas the 24th well served as negative control. Any appearance of red button was observed in all wells except the 24th well that represented the virus HA titre.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>11813</offset><text>NDV titre for treatment</text></passage><passage><infon key="file">Tab1.xml</infon><infon key="id">Tab1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>11837</offset><text>Showed preparation of virus titres from 108 to get 8, 16, 32 and 64 HA units</text></passage><passage><infon key="file">Tab1.xml</infon><infon key="id">Tab1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Virus Titre&lt;/th&gt;&lt;th&gt;Dilution&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;8 HA virus titre&lt;/td&gt;&lt;td&gt;1 part of NDV (10&lt;sup&gt;8&lt;/sup&gt;) or 100 ul + 900 mul PBS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;16 HA virus titre&lt;/td&gt;&lt;td&gt;1 part of NDV (10&lt;sup&gt;8&lt;/sup&gt;) or 100 ul + 800 mul PBS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;32 HA virus titre&lt;/td&gt;&lt;td&gt;1 part of NDV (10&lt;sup&gt;8&lt;/sup&gt;) or 100 ul + 700 mul PBS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;64 HA virus titre&lt;/td&gt;&lt;td&gt;1 part of NDV (10&lt;sup&gt;8&lt;/sup&gt;) or 100 ul + 600 mul PBS&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>11914</offset><text>Virus Titre	Dilution	 	8 HA virus titre	1 part of NDV (108) or 100 ul + 900 mul PBS	 	16 HA virus titre	1 part of NDV (108) or 100 ul + 800 mul PBS	 	32 HA virus titre	1 part of NDV (108) or 100 ul + 700 mul PBS	 	64 HA virus titre	1 part of NDV (108) or 100 ul + 600 mul PBS	 	</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12217</offset><text>Viruses were prepared from titre of 108 (28) where it was neatly harvested from chicken eggs. Then the viruses were diluted to 8 HA, 16 HA, 32 HA and 64 HA unit of NDV as described in the Table 1 below.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>12420</offset><text>Cell culture</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12433</offset><text>Mouse mammary tumour cell line (4 T1) was obtained from the American Type Culture Collection (ATCC). Cell was cultured in RPMI-1640 medium that was supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were maintained at 37  C in a humidified atmosphere of 5% CO2 in air. Culture medium was replaced every 2 to 3 days until the cell become 90% confluence before being subculture or used in the further experiment.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>12879</offset><text>Animals and xenograft mouse mammary tumour model</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12928</offset><text>Healthy BALB/c mice weighing 15-20 g of age between 6 and 7 weeks old were obtained from Institute of Medical Research (IMR, Malaysia). The animals were reared in the animal house of Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, where they were kept in a sterile plastic cage under hygienic conditions and were provided with food and water ad labium. Studies were conducted in Cancer Research Laboratory of Institute of Bioscience. All the animal works were conducted in accordance with institutional guidelines for Animal Care and Use Committee (ACUC), Faculty of Medicine and Health Sciences, Universiti Putra Malaysia. A concentration of 1 x 104 cells/ml (0.1 cc injection per mouse) was used to induced tumour in the mice. The animals were not subjected to any form of suffering during the induction process. Subcutaneous (s.c.) injection of 4 T1 breast tumour cells was made into the mammary gland by gently penetrating the skin. All animals used in this experiment were humanely euthanized by CO2 asphyxiation upon meeting the criteria for tumour burden usually considered to be &gt;=150mm3.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>14061</offset><text>Experimental design and NDV treatment</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14099</offset><text>Total 90 mice were used in this study and they divided into 15 groups (10 allotransplanted and 5 normal) with each group consisted of 6 mice. The normal category comprised of 5 groups of mice that were treated with 8, 16, 32 and 64 HA NDV without xenotransplant of cancer cells (NDV), while, a group that is only treated with normal feeding (without NDV and cancer cells) was served as control (NC). On the other hand, another 10 groups were allotransplanted with 4 T1 breast cancer cells, which are under xenotransplantation category. Out of 10 groups, 4 groups were received 0.1 cc of 0.5 mug/ml Tamoxifen in combination with 8, 16, 32 and 64 HA of NDV, respectively (CNDV+T); another 4 groups were treated with 0.1 cc of 8, 16, 32 and 64 HA of NDV only (CNDV), respectively. A group of allotransplanted mice without subjected to any virus or tamoxifen was served as cancer control (CC), while, another group was only treated with 0.1 cc of 0.5 mug/ml tamoxifen was served as positive control (CT).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>15112</offset><text>Tumour, body weight and mortality</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15146</offset><text>The body weight and tumour weight of the mice were measured on the first and last day after inoculation with NDV and allotransplanted with 4 T1 breast cancer cells. The mortality rate of the mice for each group was also assessed every day until day 28 to determine the effect of NDV, NDV + Tamoxifen on the survival rate of the mice.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>15487</offset><text>Analysis of liver function</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15514</offset><text>For assessment of liver function, plasma enzyme activities of total bilirubin level, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined using an automated enzyme activity analyser (Beckman, USA).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>15743</offset><text>Cytokine determination by Cytometric Bead Array (CBA)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>15797</offset><text>Measurement of interleukin-6 (IL-6) (Cat. No: 555240), interleukin-10 (IL-10) (Cat. No: 555252) interleukin-12p70 (IL-12p70) (Cat. No: 555256), interferon-gamma (IFN-gamma) (Cat. No: 555138), monocyte chemoattractant protein-1 (MCP-1) (Cat. No: 555260), and tumour necrosis factor-alpha (TNF-alpha) (Cat. No: 558874), were performed using a mouse inflammation cytometric bead array kits (CBA; BD Biosciences, Malaysia). The assay protocol was done strictly according to the manufacturer's instructions and the samples were analyzed with flow cytometer incorporated BD FACSComp  software.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>16385</offset><text>Determination of cytokines by Enzyme-Linked Immunosorbent Spot (ELISPOT)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16458</offset><text>Spleen cells suspension was prepared according to the method by Yang et al. with slight modified. Spleen was removed and placed in plates containing Hank's balanced salt solution (HBSS) under sterile techniques. Spleen was then cut into small pieces and mashed through a nylon sieve. Clumps and debris were removed by allowing them to settle down before the cell suspension was transferred to clean centrifuge tube. Cell suspension was then centrifuged at 200 g, 4  C for 15 min. Supernatant was discarded and cells were gently re-suspended with red cell lysing buffer in order to lyse erythrocytes. Again, the cell suspension was centrifuged at 200 g, 4  C for 5 min to remove cell debris and ghosts. After 2 washing in cold HBSS, the mononuclear cells were counted by trypan blue exclusion. Cell concentration was adjusted to the 1.5 to 3.0 x 105 cells/ml in cell culture medium and kept on ice until further use. The ELISPOT assays were conducted by using the IL-6, IL-10, MCP-1, TNF-alpha, IFN-gamma and IL-12p70 ELISPOT kit (BD Biosciences, Malaysia) according to the manufacturer's protocol. Samples were run in quadruplicates. The numbers of spots were enumerated manually by inspection under a dissecting microscope and automated ELISPOT plate reader.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>17735</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>17756</offset><text>Data are expressed as Mean +- S.D. and analyses were done using Statistical Package for Social Sciences (SPSS version 22). Comparison between groups was determined by ANOVA and Dunnet test as post-hoc analysis was applied. P &lt; 0.05 was considered as significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>18027</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>18035</offset><text>Effect of NDV on body weight and tumour weight in allotransplanted mice</text></passage><passage><infon key="file">Tab2.xml</infon><infon key="id">Tab2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>18107</offset><text>Effect of velogenic viscerotropic (VVNDV) AF2240 and tamoxifen in mortality rate, body and tumour weight of mice</text></passage><passage><infon key="file">Tab2.xml</infon><infon key="id">Tab2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;2&quot;&gt;Group&lt;/th&gt;&lt;th colspan=&quot;3&quot;&gt;Animal number&lt;/th&gt;&lt;th colspan=&quot;2&quot;&gt;Body weight +- SD&lt;/th&gt;&lt;th rowspan=&quot;2&quot;&gt;Tumour weight (g)&lt;/th&gt;&lt;th rowspan=&quot;2&quot;&gt;Inhibition&lt;break/&gt;(%)&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th&gt;Beginning&lt;/th&gt;&lt;th&gt;End&lt;/th&gt;&lt;th&gt;Mortality rate (%)&lt;/th&gt;&lt;th&gt;Beginning&lt;/th&gt;&lt;th&gt;End&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;CC&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.66 +- 0.70&lt;/td&gt;&lt;td&gt;21.26 +- 1.24 *&lt;/td&gt;&lt;td&gt;1.45 +- 0.43&lt;/td&gt;&lt;td&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CT&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.48 +- 0.09&lt;/td&gt;&lt;td&gt;20.88 +- 0.79 *&lt;/td&gt;&lt;td&gt;1.21 +- 0.41&lt;/td&gt;&lt;td&gt;16.55&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;8&quot;&gt;CNDV&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 8HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.77 +- 0.11&lt;/td&gt;&lt;td&gt;19.49 +- 0.30 *&lt;/td&gt;&lt;td&gt;NG &lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 16HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.64 +- 0.32&lt;/td&gt;&lt;td&gt;19.30 +- 0.06 *&lt;/td&gt;&lt;td&gt;NG &lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 32HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.86 +- 0.10&lt;/td&gt;&lt;td&gt;19.45 +- 0.10 *&lt;/td&gt;&lt;td&gt;NG &lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 64HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.54 +- 0.31&lt;/td&gt;&lt;td&gt;19.66 +- 0.13 *&lt;/td&gt;&lt;td&gt;NG &lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;8&quot;&gt;CNDV + T&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 8HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.93 +- 0.41&lt;/td&gt;&lt;td&gt;19.33 +- 0.16 *&lt;/td&gt;&lt;td&gt;NG &lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 16HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.86 +- 0.14&lt;/td&gt;&lt;td&gt;19.50 +- 0.30 *&lt;/td&gt;&lt;td&gt;NG &lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 32HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.87 +- 0.06&lt;/td&gt;&lt;td&gt;21.00 +- 0.40 *&lt;/td&gt;&lt;td&gt;2.27 +- 0.28&lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;-56.55&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt; 64HA NDV&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;0&lt;/td&gt;&lt;td&gt;16.66 +- 0.06&lt;/td&gt;&lt;td&gt;20.59 +- 0.36 *&lt;/td&gt;&lt;td&gt;3.64 +- 0.23&lt;sup&gt;#&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;-151.03&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>18221</offset><text>Group	Animal number	Body weight +- SD	Tumour weight (g)	Inhibition(%)	 	Beginning	End	Mortality rate (%)	Beginning	End	 	CC	6	6	0	16.66 +- 0.70	21.26 +- 1.24 *	1.45 +- 0.43	-	 	CT	6	6	0	16.48 +- 0.09	20.88 +- 0.79 *	1.21 +- 0.41	16.55	 	CNDV	 	 8HA NDV	6	6	0	16.77 +- 0.11	19.49 +- 0.30 *	NG #	100	 	 16HA NDV	6	6	0	16.64 +- 0.32	19.30 +- 0.06 *	NG #	100	 	 32HA NDV	6	6	0	16.86 +- 0.10	19.45 +- 0.10 *	NG #	100	 	 64HA NDV	6	6	0	16.54 +- 0.31	19.66 +- 0.13 *	NG #	100	 	CNDV + T	 	 8HA NDV	6	6	0	16.93 +- 0.41	19.33 +- 0.16 *	NG #	100	 	 16HA NDV	6	6	0	16.86 +- 0.14	19.50 +- 0.30 *	NG #	100	 	 32HA NDV	6	6	0	16.87 +- 0.06	21.00 +- 0.40 *	2.27 +- 0.28#	-56.55	 	 64HA NDV	6	6	0	16.66 +- 0.06	20.59 +- 0.36 *	3.64 +- 0.23#	-151.03	 	</text></passage><passage><infon key="file">Tab2.xml</infon><infon key="id">Tab2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>19042</offset><text>Results expressed in mean +- S.D. *p &lt; 0.05 compared with beginning body weight; #p &lt; 0.05 compared with cancer control (CC). CT, allotransplanted + tamoxifen; CNDV, allotransplanted + virus; CNDV+T, allotransplanted + virus + Tamoxifen; NG, negative</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19305</offset><text>All groups of mice showed significant increment in body weight compared with beginning stage (Table 2). On the other hand, the tumour in all groups increased in size, weight and no signs of regression at the end of the experiment except for groups CNDV8, 16, 32, 64, CNDV8 + T and CNDV16 + T (Table 2). The six groups mentioned above did not show any tumour growth at all. Thus, the percentage of inhibition was up to 100%. In contrast, groups CNDV32 + T and CNDV64 + T did not show any signs of inhibition, and it seems there is an enhanced tumour growth. CT group which was treated Tamoxifen, a reference drug, showed slightly weak tumour suppression of about 16.55%.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>19991</offset><text>Liver function test</text></passage><passage><infon key="file">Tab3.xml</infon><infon key="id">Tab3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>20011</offset><text>Activities of ALT, AST and the level of total bilirubin in different groups of mice</text></passage><passage><infon key="file">Tab3.xml</infon><infon key="id">Tab3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th colspan=&quot;4&quot;&gt;Liver Function Tests&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th&gt;Groups&lt;/th&gt;&lt;th&gt;Total Bilirubin [mg/dl]&lt;/th&gt;&lt;th&gt;Aspartate Transaminase (AST) [U/l]&lt;/th&gt;&lt;th&gt;Alanine Transaminase (ALT) [U/l]&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;NC&lt;/td&gt;&lt;td&gt;3.43 +- 0.40&lt;/td&gt;&lt;td&gt;120.67 +- 1.53&lt;/td&gt;&lt;td&gt;36.00 +- 2.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CC&lt;/td&gt;&lt;td&gt;2.13 +- 0.95&lt;/td&gt;&lt;td&gt;214.67 +- 1.53 *&lt;/td&gt;&lt;td&gt;53.67 +- 1.53&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CT&lt;/td&gt;&lt;td&gt;5.27 +- 0.59&lt;/td&gt;&lt;td&gt;265.00 +- 2.00 *&lt;/td&gt;&lt;td&gt;95.67 +- 1.53 *&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;NDV8&lt;/td&gt;&lt;td&gt;4.43 +- 0.40&lt;/td&gt;&lt;td&gt;153.33 +- 1.53&lt;/td&gt;&lt;td&gt;38.67 +- 1.53&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;NDV16&lt;/td&gt;&lt;td&gt;5.75 +- 0.35&lt;/td&gt;&lt;td&gt;125.33 +- 93.82&lt;/td&gt;&lt;td&gt;41.67 +- 1.53&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;NDV32&lt;/td&gt;&lt;td&gt;4.87 +- 0.35&lt;/td&gt;&lt;td&gt;105.00 +- 1.00&lt;/td&gt;&lt;td&gt;47.00 +- 1.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;NDV64&lt;/td&gt;&lt;td&gt;5.13 +- 0.67&lt;/td&gt;&lt;td&gt;115.00 +- 11.27&lt;/td&gt;&lt;td&gt;52.67 +- 2.51&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV8&lt;/td&gt;&lt;td&gt;4.47 +- 0.35&lt;/td&gt;&lt;td&gt;98.67 +- 1.53&lt;/td&gt;&lt;td&gt;26.33 +- 1.15&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV16&lt;/td&gt;&lt;td&gt;3.00 +- 0.50&lt;/td&gt;&lt;td&gt;173.33 +- 1.53&lt;/td&gt;&lt;td&gt;57.00 +- 1.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV32&lt;/td&gt;&lt;td&gt;2.87 +- 0.35&lt;/td&gt;&lt;td&gt;121.00 +- 2.00&lt;/td&gt;&lt;td&gt;49.00 +- 1.00&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV64&lt;/td&gt;&lt;td&gt;3.40 +- 0.40&lt;/td&gt;&lt;td&gt;153.67 +- 1.53&lt;/td&gt;&lt;td&gt;49.33 +- 0.58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV8 + T&lt;/td&gt;&lt;td&gt;2.77 +- 0.45&lt;/td&gt;&lt;td&gt;166.67 +- 56.62&lt;/td&gt;&lt;td&gt;103.00 +- 2.00 *&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV16 + T&lt;/td&gt;&lt;td&gt;2.43 +- 0.40&lt;/td&gt;&lt;td&gt;108.00 +- 1.00&lt;/td&gt;&lt;td&gt;56.33 +- 1.53&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV32 + T&lt;/td&gt;&lt;td&gt;10.67 +- 4.72 *&lt;/td&gt;&lt;td&gt;122.33 +- 2.52&lt;/td&gt;&lt;td&gt;160.33 +- 25.66 *&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CNDV64 + T&lt;/td&gt;&lt;td&gt;14.33 +- 4.04 *&lt;/td&gt;&lt;td&gt;170.67 +- 1.53&lt;/td&gt;&lt;td&gt;146.33 +- 32.52 *&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>20095</offset><text>Liver Function Tests	 	Groups	Total Bilirubin [mg/dl]	Aspartate Transaminase (AST) [U/l]	Alanine Transaminase (ALT) [U/l]	 	NC	3.43 +- 0.40	120.67 +- 1.53	36.00 +- 2.00	 	CC	2.13 +- 0.95	214.67 +- 1.53 *	53.67 +- 1.53	 	CT	5.27 +- 0.59	265.00 +- 2.00 *	95.67 +- 1.53 *	 	NDV8	4.43 +- 0.40	153.33 +- 1.53	38.67 +- 1.53	 	NDV16	5.75 +- 0.35	125.33 +- 93.82	41.67 +- 1.53	 	NDV32	4.87 +- 0.35	105.00 +- 1.00	47.00 +- 1.00	 	NDV64	5.13 +- 0.67	115.00 +- 11.27	52.67 +- 2.51	 	CNDV8	4.47 +- 0.35	98.67 +- 1.53	26.33 +- 1.15	 	CNDV16	3.00 +- 0.50	173.33 +- 1.53	57.00 +- 1.00	 	CNDV32	2.87 +- 0.35	121.00 +- 2.00	49.00 +- 1.00	 	CNDV64	3.40 +- 0.40	153.67 +- 1.53	49.33 +- 0.58	 	CNDV8 + T	2.77 +- 0.45	166.67 +- 56.62	103.00 +- 2.00 *	 	CNDV16 + T	2.43 +- 0.40	108.00 +- 1.00	56.33 +- 1.53	 	CNDV32 + T	10.67 +- 4.72 *	122.33 +- 2.52	160.33 +- 25.66 *	 	CNDV64 + T	14.33 +- 4.04 *	170.67 +- 1.53	146.33 +- 32.52 *	 	</text></passage><passage><infon key="file">Tab3.xml</infon><infon key="id">Tab3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>21113</offset><text>NC normal control, CC cancer contro; CT allotransplanted + Tamoxifen, NDV virus alone; CNDV, allotransplanted + virus; CNDV + T, allotransplanted + virus + Tamoxifen; n = 6. Data are shown as mean +- S.D. *p &lt; 0.05 compared with NC</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21347</offset><text>The activity of serum AST, ALT and the level of total bilirubin for all the treated groups are shown in Table 3. The level of total bilirubin for all groups, except for CNDV32 + T and CNDV 64 + T groups, showed no significant difference compared with the normal control group. Both treatments indicated a markedly elevated level of total bilirubin. In the case of enzyme activities, cancer control (CC), reference drug (CT), CNDV16 and CNDV64 + T significantly increased AST activity. This is especially apparent in the group treated with Tamoxifen (CT), which showed an increase one-fold higher than the normal control. On the other hand, groups CT, CNDV8 + T, CNDV32 + T and CNDV64 + T showed a significant increment of ALT activity as compared to normal control.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>22137</offset><text>Cytokine analysis of the plasma/ serum by CBA assay</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22189</offset><text>Approximately one milliliter of plasma/serum from mice was collected following CA Argmann and J Auwerx technique at week 1, 2, 3 and 4 from each group setting and cytokine concentrations were measured by CBA assay. A total of six different cytokines were determined, i.e. IL-6, IFN-gamma, MCP-1, IL-10, IL-12p70 and TNF-alpha. Among all the cytokines that were measured, the concentration of IL-6, MCP-1 and IL-12p70 in the group of cancer control (CC) were found to have a significant increase throughout the four weeks compared with normal control. In addition, CC group was found to produce the highest level of IL-6, MCP-1 and IL-12p70 (54.2 +- 8.7 pg/ml, 40.1 +- 2.4 pg/ml, 11.2 +- 2.9 pg/ml of, respectively), compared to normal control which are only 9.5 +- 1.2 pg/ml, 4.1 +- 0.1 pg/ml and 0.8 +- 0.1 pg/ml, respectively [Additional file 1: Table S1, Additional file 2: Table S2, Additional file 3: Table S3]. On the other hand, CC, CT, CNDV8, 16, 32 and 64 significantly produced IL-10 throughout the four weeks. However, production of IL-10 by group CNDV 16 ceased in week 3 and 4 [Additional file 4: Table S4]. There is no expression of IL-10 in the group NDV8-64. Apart from that, CC, CT, CNDV16 + T, CNDV32 + T and CNDV64 + T showed relatively high secretion of TNF-alpha throughout the experiment [Additional file 5: Table S5]. In the case of IFN-gamma, all groups showed varying results in different week and consider relatively low production [Additional file 6: Table S6].</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>23717</offset><text>Detection of spleen produced-cytokine by ELISPOT</text></passage><passage><infon key="file">12885_2019_5516_Fig1_HTML.jpg</infon><infon key="id">Fig1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>23766</offset><text>Number spots of IL-6 (in pg/ml) in different groups of mice throughout four weeks experiment. NC: Normal Control; CC: Cancer Control; CT: Cancer + Tamoxifen; NDV: NDV virus alone; CNDV: Cancer and treated with NDV virus; CNDV + T: Cancer and treated with NDV and Tamoxifen. a
p &lt; 0.05 compared with NC; b
p &lt; 0.05 compared with CC</text></passage><passage><infon key="file">12885_2019_5516_Fig2_HTML.jpg</infon><infon key="id">Fig2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>24105</offset><text>Number spots of MCP-1 (in pg/ml) in different groups of mice throughout four weeks experiment. NC: Normal Control; CC: Cancer Control; CT: Cancer + Tamoxifen; NDV: NDV virus alone; CNDV: Cancer and treated with NDV virus; CNDV + T: Cancer and treated with NDV and Tamoxifen. a
p &lt; 0.05 compared with NC; b
p &lt; 0.05 compared with CC</text></passage><passage><infon key="file">12885_2019_5516_Fig3_HTML.jpg</infon><infon key="id">Fig3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>24445</offset><text>Number spots of IL-12 (in pg/ml) in different groups of mice throughout four weeks experiment. NC: Normal Control; CC: Cancer Control; CT: Cancer + Tamoxifen; NDV: NDV virus alone; CNDV: Cancer and treated with NDV virus; CNDV + T: Cancer and treated with NDV and Tamoxifen. a
p &lt; 0.05 compared with NC; b
p &lt; 0.05 compared with CC</text></passage><passage><infon key="file">12885_2019_5516_Fig4_HTML.jpg</infon><infon key="id">Fig4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>24785</offset><text>Number spots of IL-10 (in pg/ml) in different groups of mice throughout four weeks experiment. NC: Normal Control; CC: Cancer Control; CT: Cancer + Tamoxifen; NDV: NDV virus alone; CNDV: Cancer and treated with NDV virus; CNDV + T: Cancer and treated with NDV and Tamoxifen. a
p &lt; 0.05 compared with NC; b
p &lt; 0.05 compared with CC</text></passage><passage><infon key="file">12885_2019_5516_Fig5_HTML.jpg</infon><infon key="id">Fig5</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>25125</offset><text>Number spots of TNF-alpha (in pg/ml) in different groups of mice throughout four weeks experiment. NC: Normal Control; CC: Cancer Control; CT: Cancer + Tamoxifen; NDV: NDV virus alone; CNDV: Cancer and treated with NDV virus; CNDV + T: Cancer and treated with NDV and Tamoxifen. a
p &lt; 0.05 compared with NC; b
p &lt; 0.05 compared with CC</text></passage><passage><infon key="file">12885_2019_5516_Fig6_HTML.jpg</infon><infon key="id">Fig6</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>25466</offset><text>Number spots of IFN-gamma (in pg/ml) in different groups of mice throughout four weeks experiment. NC: Normal Control; CC: Cancer Control; CT: Cancer + Tamoxifen; NDV: NDV virus alone; CNDV: Cancer and treated with NDV virus; CNDV + T: Cancer and treated with NDV and Tamoxifen. a
p &lt; 0.05 compared with NC; b
p &lt; 0.05 compared with CC</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>25807</offset><text>To determine the role of NDV virus induced - cytokines in suppressing 4 T1 breast cancer, mice splenocytes cytokine production was measured after inoculation with NDV virus throughout the experimental period. Cancer control group (CC) possessed relatively high secretion of IL-6, IFN-gamma, MCP-1, IL-10, IL-12p70 and TNF-alpha from week 1 until week 4 compared with other groups [Figs. 1, 2, 3, 4, 5 and 6]. Groups that were treated with NDV virus alone did not show any significant difference compared with normal control (NC) group in all the cytokine measurement. In the case of all the transplanted category, group treated with virus alone (CNDV) secreted relatively high level of cytokines when compared with the group treated with combination of virus and tamoxifen (CNDV+T). On the other hand, there was no cytokines observed in normal control group.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>26666</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26677</offset><text>Virotherapy has emerged as a novel and potential anticancer agent in recent years. Some viruses have oncolytic properties. Due to its unique mechanism of action and its ability to impact on many types of human cancer, NDV has been proposed as a potent anti-cancer agent. Many strains of NDV were found to exhibit anti-cancer activity, for instance, MTH-68/H and AF2240 exhibited its anti-tumour effect via induction of nitric oxide synthesis from macrophages. In addition, systemic therapy with NDV strain PV701 showed a promising result as an important therapy for patients with a solid tumour. Apart from that, other strains of NDV that have been investigated are HUJ, 73-T, V4UPM and AF2240.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27372</offset><text>There are two strains of NDV that can be found commonly in Malaysia, namely AF2240 and V4-UPM. In our previous studies, exposure of NDV AF2240 showed an apoptotic effect against breast tumour cells. However, the underlying mechanism of action on how NDV AF2240 kills the breast cancer cells remains largely unclear. In order to understand the mechanism of action, the current study evaluated the serological effects of NDV AF2240 inoculation in enhancing breast tumour by inhibiting cytokines secretion by the host immune system. In addition, the effect of NDV AF2240 on the liver was evaluated using liver function test throughout.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>28006</offset><text>Based on in vivo pilot study conducted prior to this experiment, the minimum effective dosage required to suppress tumour cell by NDV AF2240 was 8HA (data not shown). Therefore, the dosage that was used in the current study started from 8HA up to 64HA. Due to this, the effect of high concentration of NDV AF2240 on body weight and mortality rate were investigated throughout the experiment. Interestingly, the results of the present study indicated that the NDV AF2240 was tolerated in mice even at 64HA. In addition, there were no significant adverse physical changes observed in the body weight and food intake of mice in the treated groups as compared to control group. Several studies reported that pre- and post-operative cancer patients show weight loss or cachexia. However, the overall body weight increased over time in the present study. Thus, it is most likely that the increased in weight maybe due to the tumour itself. In the case of tumour growth profile, tumour growth in all transplanted 4 T1 breast cancer cells groups were completely inhibited due to treatment with NDV alone. Conversely, low concentration of NDV + Tamoxifen (8 and 16HA) completely suppressed tumour growth, while at high concentrations (32 and 64HA), enhanced tumour cell growth was observed. Therefore, it is believed that there may have been some antagonistic effect between high titre of NDV with tamoxifen, neither allowing NDV nor tamoxifen to execute its effect in killing 4 T1 tumour cells.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29501</offset><text>In order to evaluate the hepatotoxicity caused by the NDV as well as a combination of NDV and tamoxifen, liver biochemical parameters such as total bilirubin, AST and ALT were determined. Plasma concentrations of bilirubin, ALT and AST can be used as good indicators of the functionality and cellular integrity of the liver. In addition, they are also good biomarkers that are used to predict any possible toxicity. The present study demonstrated a significant elevation of bilirubin; AST and ALT in CNDV+T (32 and 64 HA) group compared to normal control. Moreover, the group treated with tamoxifen alone also showed significant increment in AST and ALT. This suggests that the high titre of NDV with tamoxifen or tamoxifen may cause damage to hepatocytes. Indeed, several studies revealed that tamoxifen might cause toxic hepatitis, cirrhosis and sub massive hepatic necrosis. In terms of liver function enzymes, ALT is a more specific indicator of liver function, as compared to AST, which can also be found in red blood cells, cardiac and skeletal muscle. Increased level of bilirubin may also indicate liver disease, biliary structure, cardiac problem and neonatal hyperbilirubinaemia. Therefore, careful consideration in interpreting the bilirubin level, ALT and AST enzyme activity has to be made with regards to findings from this study. Moreover, many factors can contribute to the elevation of the parameters observed here.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>30934</offset><text>The current study showed that inoculation of NDV AF2240 could be beneficial for the treatment of breast cancer, but little is known about its mechanism of action. In order to elucidate a possible mechanism for the anti-neoplastic activity of NDV, immunological effects induced by NDV AF2240 was evaluated by determining the following cytokines; IL-6, IL-10, IL-12p70, IFN-gamma, TNF-alpha and MCP-1. All the cytokines were measured by using ELISPOT and cytometric bead array assay. Many cytokines are known to be involved in inhibiting or enhancing tumour growth. For instance, IL-6, an inflammatory cytokine, is known to mediate many undesired, detrimental effects that contribute to cardiovascular disease, bowel disease and Alzheimer disease. In addition, IL-6 was found to pathologically regulate various types of cancer, including colorectal cancer, lung cancer and breast cancer. Recent studies reported that up-regulation of IL-6 level leads to cancer cells resistance to chemotherapeutic drugs. It seems capable of protecting cells from damage by free radicals and this effect extends to the cells that might have escaped from normal cell cycle pathway. Interestingly, findings reported here showed a significant suppression of IL-6 in the breast cancer-bearing mice challenged with NDV (8-64HA) and a combination of NDV and tamoxifen (8-64HA) compared with cancer control group (CC). Hence, NDV suppressed tumour growth may be through the impairment of IL-6 secretion.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32412</offset><text>As TNF-alpha is considered as a potential candidate for virotherapy in cancer patients, we have further analyzed the expression level for TNF-alpha in NDV treated 4 T1 breast cancer model. There are two mechanisms proposed for the antineoplastic activity of NDV: TNF-alpha secretion by activated peripheral blood mononuclear cells and enhancement in sensitivity of neoplastic cells towards TNF-alpha. In addition, recent studies also demonstrated that NDV induced apoptosis process mediated by TNF. A part from that, it is also shown to enhance vascular permeability, facilitating the uptake and accumulation of chemotherapeutic drugs. Hence, TNF-alpha therapy is a promising antineoplastic treatment. Present results revealed a marked increase of TNF-alpha concentration in 4 T1 breast cancer bearing mice challenged with a combination of NDV AF2240 and tamoxifen. Although the result for cancer control is higher in CBA assay compared with ELISPOT, this may be that the cytokine-producing cell measurements done by using ELISPOT did not account for productivity per individual cells. Thus, it does not allow the differentiation on whether few cells produce many cytokines or many cells produce little cytokines as shown by CBA assay.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>33648</offset><text>IL-12 is capable of evoking a potent immune response and also down-regulates the formation of new blood vessels into growing tumour. IFN-gamma is known as the key downstream factor induced by IL-12. Thus, the antitumour activity exerted by IL-12 is believed largely to be due to the local IFN-gamma production and subsequent activation of the angiostatic chemokines IP-10. Nastala and her colleagues reported that the tumour regression induced by recombinant IL-12 is associated with the production of IFN-gamma. Hence, IL-12 therapy is crucial for cell-mediated-antitumour activity. However, results from this study revealed that treatment with NDV or NDV + tamoxifen induces sustained low concentration of IL-12 and IFN-gamma in breast cancer-bearing mice. This finding could suggest that NDV induces tumour regression via other signaling molecules or cytokines, but not IL-12 - IFN-gamma pathway.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>34548</offset><text>IL-10 is known to play an important role in inflammation. It suppresses the activation of macrophages and dendritic cells. In addition, it also inhibits numerous innate immune response and is associated with inflammatory activities. On the other hand, high secretion of IL-10 has been found in various types of cancer cell, including breast, kidney, colon, lung and pancreas cancer. In the context of breast cancer, IL-10 may act as a two-edged sword. Elevation of IL-10 level could facilitate the development of cancer by supporting tumour cell escape from host immune response via activation of PRL-R variants with altered pro-inflammatory or abrogated function. On the other hand, IL-10 could also prevent or reduce tumour growth and metastasis via suppression of angiogenesis. Current results showed that cancer control (CC) group expressed a high level of IL-10, and this is similar to the studies done by Kozlowski et al. and Razmkhah et al.. Interestingly, breast cancer-bearing mice treated with a combination of NDV and tamoxifen showed a reduction in IL-10. Hence, it could be suggested that NDV + tamoxifen exhibited a synergistic effect, which prevents cancer growth through suppression of IL-10 secretion.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>35771</offset><text>Lastly, the role of monocytes chemotactic protein-1 (MCP-1) was also evaluated in the current study. Several studies documented that upregulation of MCP-1 could assist in tumour growth by neovascularization. In addition, a clinical study done by Lebrecht et al. reported that elevation of the MCP-1 level correlated with advanced tumour stage and lymph node involvement in patients with breast cancer. Current data showed that there is only slight reduction of MCP-1 level in cancer bearing-mice treated with NDV alone or combination of NDV and tamoxifen compared to CC group. High concentration of MCP-1 found in CC could be due to release by cancer cells or inflammation. Thus, NDV induced tumour regression may not be through suppression of MCP-1 pathway.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>36530</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>36542</offset><text>Based on the findings mentioned above, our data support that NDV AF2240 could potentially serve as an alternative treatment for breast cancer therapy. The dose or titre for virus needs proper research and study for its efficacy and safety use. A part from that, NDV AF2240 induced tumour regression may act through up-regulation or down-regulation of different cytokines. However, further experimental studies need to be carry out   and in vivo to decipher the molecular mechanism underlaying tumour cytolysis and cytokines released due to NDV infection.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>37102</offset><text>Additional files</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title</infon><offset>37119</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37133</offset><text>CC</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37136</offset><text>Cancer Control</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37151</offset><text>CNDV + T</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37160</offset><text>Cancer and treated with NDV and Tamoxifen</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37202</offset><text>CNDV</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37207</offset><text>Cancer and treated with NDV virus</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37241</offset><text>CT</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37244</offset><text>Cancer + Tamoxifen</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37263</offset><text>IFN-gamma</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37273</offset><text>Interferon gamma</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37290</offset><text>IL-10</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37296</offset><text>Interleukin 10</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37311</offset><text>IL12p70</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37319</offset><text>Interleukin 12</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37334</offset><text>IL-6</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37339</offset><text>Interleukin 6</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37353</offset><text>MCP-1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37359</offset><text>Monocyte chemoattractant protein-1</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37394</offset><text>NC</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37397</offset><text>Normal Control</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37412</offset><text>NDV</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37416</offset><text>Newcastle disease virus</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37440</offset><text>NG</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37443</offset><text>Negative</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37452</offset><text>TNF-alpha</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37462</offset><text>Tumour necrosis factor alpha</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37491</offset><text>VVNDV</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>37497</offset><text>Velogenic Viscerotropic</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title</infon><offset>37521</offset><text>Author's Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>37546</offset><text>FO, JR, UA, ZE, AR and AI participated in the design of the research. JR carried out the experiments and analysed the data with the help from UA and ZE. YYK and UA analysed the data and wrote the paper. FO provided funding and supervised the study. All authors read and approved the final manuscript.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>37847</offset><text>Ethics approval and consent to participate</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>37890</offset><text>This study was conducted in accordance with the recommendations from the guidelines provided by the Institutional Animal Care and Use Committee (IACUC) of the Faculty of Medicine and Health Sciences (FMHS), Universiti Putra Malaysia (UPM). The protocol was approved and monitored by the Ethics Research Committee of the Universiti Putra Malaysia.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>38237</offset><text>Consent for publication</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>38261</offset><text>Not applicable.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>38277</offset><text>Competing interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>38296</offset><text>The authors declare that they have no competing interests.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>38355</offset><text>Publisher's Note</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>38374</offset><text>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>38493</offset><text>References</text></passage><passage><infon key="fpage">89</infon><infon key="name_0">surname:Omar;given-names:ZA</infon><infon key="name_1">surname:NSI;given-names:T</infon><infon key="section_type">REF</infon><infon key="source">Malaysia Cancer Statistics-Data and Figure</infon><infon key="type">ref</infon><infon key="year">2011</infon><offset>38504</offset><text>National Cancer Registry Report 2007</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>38541</offset><text>Azizah AM, Nor Saleha IT, Noor Hashima A, Asmah ZA, Mastulu W. Malaysian National Cancer Registry Report 2007-2011. Malaysia Cancer Statistics - Data and Figure 2007. Malaysia cancer statistics, data and figure. Putrajaya: National Cancer Institute, Ministry of Health; 2016 </text></passage><passage><infon key="fpage">369</infon><infon key="issue">3</infon><infon key="lpage">374</infon><infon key="name_0">surname:Yip;given-names:CH</infon><infon key="name_1">surname:Taib;given-names:NA</infon><infon key="name_2">surname:Mohamed;given-names:I</infon><infon key="pub-id_pmid">17059323</infon><infon key="section_type">REF</infon><infon key="source">Asian Pac J Cancer Prev</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2006</infon><offset>38821</offset><text>Epidemiology of breast cancer in Malaysia</text></passage><passage><infon key="fpage">507</infon><infon key="issue">2</infon><infon key="lpage">517</infon><infon key="name_0">surname:Jordon;given-names:V</infon><infon key="pub-id_pmid">8242225</infon><infon key="section_type">REF</infon><infon key="source">Br J Pharmacol</infon><infon key="type">ref</infon><infon key="volume">110</infon><infon key="year">1993</infon><offset>38863</offset><text>Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer</text></passage><passage><infon key="fpage">309</infon><infon key="issue">2</infon><infon key="lpage">318</infon><infon key="name_0">surname:Goldenberg;given-names:MM</infon><infon key="pub-id_pmid">10211534</infon><infon key="section_type">REF</infon><infon key="source">Clin Ther</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">1999</infon><offset>38977</offset><text>Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer</text></passage><passage><infon key="fpage">43</infon><infon key="lpage">49</infon><infon key="name_0">surname:Rugo;given-names:HS</infon><infon key="pub-id_pmid">15178815</infon><infon key="section_type">REF</infon><infon key="source">Oncologist</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2004</infon><offset>39107</offset><text>Bevacizumab in the treatment of breast cancer: rationale and current data</text></passage><passage><infon key="fpage">995</infon><infon key="issue">6</infon><infon key="lpage">998</infon><infon key="name_0">surname:Bender;given-names:CMSS</infon><infon key="name_1">surname:Brufsky;given-names:AM</infon><infon key="name_2">surname:Ryan;given-names:CM</infon><infon key="name_3">surname:Vogel;given-names:VG</infon><infon key="name_4">surname:Rastogi;given-names:P</infon><infon key="name_5">surname:Cohen;given-names:SM</infon><infon key="name_6">surname:Casillo;given-names:FE</infon><infon key="name_7">surname:Berga;given-names:SL</infon><infon key="pub-id_pmid">17898668</infon><infon key="section_type">REF</infon><infon key="source">Menopause</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2007</infon><offset>39181</offset><text>Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer</text></passage><passage><infon key="fpage">170</infon><infon key="issue">2</infon><infon key="lpage">173</infon><infon key="name_0">surname:Grilli;given-names:S</infon><infon key="section_type">REF</infon><infon key="source">Ann 1st Super Sanita</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2006</infon><offset>39283</offset><text>Tamoxifen (TAM): the dispute goes on</text></passage><passage><infon key="fpage">821</infon><infon key="issue">7</infon><infon key="lpage">825</infon><infon key="name_0">surname:Stojdl;given-names:DFLB</infon><infon key="name_1">surname:Knowles;given-names:S</infon><infon key="name_2">surname:Marius;given-names:R</infon><infon key="name_3">surname:Atkins;given-names:H</infon><infon key="name_4">surname:Sonenberg;given-names:N</infon><infon key="name_5">surname:Bell;given-names:JC</infon><infon key="pub-id_pmid">10888934</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2000</infon><offset>39320</offset><text>Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus</text></passage><passage><infon key="fpage">1134</infon><infon key="issue">10</infon><infon key="lpage">1139</infon><infon key="name_0">surname:Heise;given-names:CHT</infon><infon key="name_1">surname:Johnson;given-names:L</infon><infon key="name_2">surname:Brooks;given-names:G</infon><infon key="name_3">surname:Sampson-Johannes;given-names:A</infon><infon key="name_4">surname:Williams;given-names:A</infon><infon key="name_5">surname:Hawkins;given-names:L</infon><infon key="name_6">surname:Kirn;given-names:D</infon><infon key="pub-id_pmid">11017145</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2000</infon><offset>39422</offset><text>An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy</text></passage><passage><infon key="fpage">965</infon><infon key="issue">12</infon><infon key="lpage">976</infon><infon key="name_0">surname:Parato;given-names:KASD</infon><infon key="name_1">surname:Forsyth;given-names:PA</infon><infon key="name_2">surname:Bell;given-names:JC</infon><infon key="pub-id_pmid">16294217</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Cancer</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2005</infon><offset>39517</offset><text>Recent progress in the battle between oncolytic viruses and tumours</text></passage><passage><infon key="fpage">867</infon><infon key="issue">10</infon><infon key="lpage">874</infon><infon key="name_0">surname:Markert;given-names:JMMM</infon><infon key="name_1">surname:Rabkin;given-names:SD</infon><infon key="name_2">surname:Gillespie;given-names:GY</infon><infon key="name_3">surname:Todo;given-names:T</infon><infon key="name_4">surname:Hunter;given-names:WD</infon><infon key="name_5">surname:Palmer;given-names:CA</infon><infon key="name_6">surname:Feigenbaum;given-names:F</infon><infon key="name_7">surname:Tornatore;given-names:C</infon><infon key="name_8">surname:Tufaro;given-names:F</infon><infon key="name_9">surname:Martuza;given-names:RL</infon><infon key="pub-id_pmid">10845725</infon><infon key="section_type">REF</infon><infon key="source">Gene Ther</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2000</infon><offset>39585</offset><text>Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial</text></passage><passage><infon key="fpage">593</infon><infon key="issue">7</infon><infon key="lpage">599</infon><infon key="name_0">surname:Myers;given-names:RGS</infon><infon key="name_1">surname:Harvey;given-names:M</infon><infon key="name_2">surname:Soeffker;given-names:D</infon><infon key="name_3">surname:Frenzke;given-names:M</infon><infon key="name_4">surname:Abraham;given-names:K</infon><infon key="name_5">surname:Shaw;given-names:A</infon><infon key="name_6">surname:Rozenblatt;given-names:S</infon><infon key="name_7">surname:Federspiel;given-names:MJ</infon><infon key="name_8">surname:Russell;given-names:SJ</infon><infon key="name_9">surname:Peng;given-names:KW</infon><infon key="pub-id_pmid">15746945</infon><infon key="section_type">REF</infon><infon key="source">Cancer Gene Ther</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2005</infon><offset>39711</offset><text>Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer</text></passage><passage><infon key="fpage">4553</infon><infon key="issue">12</infon><infon key="lpage">4560</infon><infon key="name_0">surname:Unno;given-names:YSY</infon><infon key="name_1">surname:Kondo;given-names:F</infon><infon key="name_2">surname:Igarashi;given-names:N</infon><infon key="name_3">surname:Wang;given-names:G</infon><infon key="name_4">surname:Shimura;given-names:R</infon><infon key="name_5">surname:Yamaguchi;given-names:T</infon><infon key="name_6">surname:Asano;given-names:T</infon><infon key="name_7">surname:Saisho;given-names:H</infon><infon key="name_8">surname:Sekiya;given-names:S</infon><infon key="name_9">surname:Shirasawa;given-names:H</infon><infon key="pub-id_pmid">15958641</infon><infon key="section_type">REF</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2005</infon><offset>39801</offset><text>Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>39893</offset><text>Zamarin D, Palese P. Oncolytic Newcastle Disease Virus for. Cancer Therapy. 2012:25-30.</text></passage><passage><infon key="fpage">85</infon><infon key="issue">1</infon><infon key="lpage">93</infon><infon key="name_0">surname:Washburn;given-names:B</infon><infon key="name_1">surname:Schirrmacher;given-names:V</infon><infon key="pub-id_pmid">12063554</infon><infon key="section_type">REF</infon><infon key="source">Int J Oncol</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2002</infon><offset>39983</offset><text>Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>40160</offset><text>Alexander DJ SD: Newcastle disease, other avian paramyxoviruses and pneumovirus infection. In: Disease of Poultry. 12 edn. Edited by YM S: Ames: Iowa State University Press; 2008: 75-100.</text></passage><passage><infon key="fpage">9522</infon><infon key="issue">17</infon><infon key="lpage">9532</infon><infon key="name_0">surname:Park;given-names:MS</infon><infon key="name_1">surname:Garcia-Sastre;given-names:A</infon><infon key="name_2">surname:Cros;given-names:JF</infon><infon key="name_3">surname:Basler;given-names:CF</infon><infon key="name_4">surname:Palese;given-names:P</infon><infon key="pub-id_pmid">12915566</infon><infon key="section_type">REF</infon><infon key="source">J Virol</infon><infon key="type">ref</infon><infon key="volume">77</infon><infon key="year">2003</infon><offset>40350</offset><text>Newcastle disease virus V protein is a determinant of host range restriction</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>40427</offset><text>Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol. 2010;84(8):3835-44.</text></passage><passage><infon key="name_0">surname:Meyyappan;given-names:N</infon><infon key="section_type">REF</infon><infon key="source">Effect Of Newcastle Disease Virus On The Mcf-7 And Mda-Mb-231 Breast Cancer Cell Lines Universiti Putra Malaysia</infon><infon key="type">ref</infon><infon key="year">2003</infon><offset>40626</offset></passage><passage><infon key="fpage">272</infon><infon key="name_0">surname:Fauziah;given-names:OOA</infon><infon key="name_1">surname:Patimah;given-names:I</infon><infon key="name_2">surname:Aini;given-names:I</infon><infon key="section_type">REF</infon><infon key="source">J Elect Micro Soc Thailand</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2002</infon><offset>40627</offset><text>Microscopic evaluation of Newcastle disease virus (NDV) a killer in chicken but a possible live saver in human</text></passage><passage><infon key="fpage">1441</infon><infon key="issue">6</infon><infon key="lpage">1452</infon><infon key="name_0">surname:Coughlin;given-names:CMSK</infon><infon key="name_1">surname:Wysocka;given-names:M</infon><infon key="name_2">surname:Aruga;given-names:E</infon><infon key="name_3">surname:Kurzawa;given-names:H</infon><infon key="name_4">surname:Chang;given-names:AE</infon><infon key="name_5">surname:Hunter;given-names:CA</infon><infon key="name_6">surname:Fox;given-names:JC</infon><infon key="name_7">surname:Trinchieri;given-names:G</infon><infon key="name_8">surname:Lee;given-names:WM</infon><infon key="pub-id_pmid">9502787</infon><infon key="section_type">REF</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="volume">101</infon><infon key="year">1998</infon><offset>40738</offset><text>Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis</text></passage><passage><infon key="fpage">e0195425</infon><infon key="issue">4</infon><infon key="name_0">surname:Yurchenko;given-names:KS</infon><infon key="name_1">surname:Zhou;given-names:P</infon><infon key="name_2">surname:Kovner;given-names:AV</infon><infon key="name_3">surname:Zavjalov;given-names:EL</infon><infon key="name_4">surname:Shestopalova;given-names:LV</infon><infon key="name_5">surname:Shestopalov;given-names:AM</infon><infon key="pub-id_pmid">29621357</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2018</infon><offset>40861</offset><text>Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model</text></passage><passage><infon key="fpage">795</infon><infon key="issue">12</infon><infon key="lpage">807</infon><infon key="name_0">surname:Yaacov;given-names:B</infon><infon key="name_1">surname:Eliahoo;given-names:E</infon><infon key="name_2">surname:Elihaoo;given-names:E</infon><infon key="name_3">surname:Lazar;given-names:I</infon><infon key="name_4">surname:Ben-Shlomo;given-names:M</infon><infon key="name_5">surname:Greenbaum;given-names:I</infon><infon key="name_6">surname:Panet;given-names:A</infon><infon key="name_7">surname:Zakay-Rones;given-names:Z</infon><infon key="pub-id_pmid">18535620</infon><infon key="section_type">REF</infon><infon key="source">Cancer Gene Ther</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2008</infon><offset>40985</offset><text>Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors</text></passage><passage><infon key="fpage">99</infon><infon key="issue">1</infon><infon key="lpage">103</infon><infon key="name_0">surname:Mazija;given-names:H</infon><infon key="name_1">surname:Cajavec;given-names:S</infon><infon key="name_2">surname:Ergotic;given-names:N</infon><infon key="name_3">surname:Ciglar-Grozdanic;given-names:I</infon><infon key="name_4">surname:Gottstein;given-names:Z</infon><infon key="name_5">surname:Ragland;given-names:WL</infon><infon key="pub-id_pmid">20408406</infon><infon key="section_type">REF</infon><infon key="source">Avian Dis</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">2010</infon><offset>41078</offset><text>Immunogenicity and safety of Queensland V4 and Ulster 2C strains of Newcastle disease virus given to maternally immune, newly hatched chickens by nebulization</text></passage><passage><infon key="fpage">634</infon><infon key="issue">5</infon><infon key="lpage">645</infon><infon key="name_0">surname:Alabsi;given-names:AM</infon><infon key="name_1">surname:Ali;given-names:R</infon><infon key="name_2">surname:Ideris;given-names:A</infon><infon key="name_3">surname:Omar;given-names:AR</infon><infon key="name_4">surname:Bejo;given-names:MH</infon><infon key="name_5">surname:Yusoff;given-names:K</infon><infon key="name_6">surname:Ali;given-names:AM</infon><infon key="pub-id_pmid">22133641</infon><infon key="section_type">REF</infon><infon key="source">Leuk Res</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2012</infon><offset>41237</offset><text>Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo</text></passage><passage><infon key="fpage">17</infon><infon key="lpage">24</infon><infon key="name_0">surname:Othman;given-names:FAIGMEAR</infon><infon key="section_type">REF</infon><infon key="source">Yakhteh Med J</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2010</infon><offset>41355</offset><text>Oncolytic effect of Newcastle disease virus AF2240 strain on the MCF-7 breast cancer cell line</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>41450</offset><text>Zamarin D, Palese P: Oncolytic Newcastle Disease Virus for Cancer Therapy Mechanisms of NDV-mediated Oncolysis. 2013, 7(3):347-367.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>41584</offset><text>Meyyapan N: Oncolytic Effect of Newcasle Disease Virus on te MCF-7 and MDA-MB-231 Breast Cancer Cell Lines. Master. Universiti Putra Library: Universiti Putra Malaysia; 2003.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>41759</offset><text>Anushia S: Effect of Newcastle Disease Virus AF2240 on Allografted 4T1 Breast Cancer Cells in BALB/c Mice. Master. Universiti Putra Library: Universiti Putra Malaysia; 2010.</text></passage><passage><infon key="fpage">163</infon><infon key="lpage">233</infon><infon key="name_0">surname:Blaskovic;given-names:DSB</infon><infon key="section_type">REF</infon><infon key="source">Virology</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">1967</infon><offset>41933</offset><text>Laboratory methods of virus transmission in multicellular organisms</text></passage><passage><infon key="fpage">439</infon><infon key="issue">5</infon><infon key="lpage">455</infon><infon key="name_0">surname:Yusoff;given-names:K</infon><infon key="name_1">surname:Tan;given-names:WS</infon><infon key="pub-id_pmid">19184932</infon><infon key="section_type">REF</infon><infon key="source">Avian Pathol</infon><infon key="type">ref</infon><infon key="volume">30</infon><infon key="year">2001</infon><offset>42001</offset><text>Newcastle disease virus: macromolecules and opportunities</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>42059</offset><text>DJ Alexander: Newcastle disease diagnosis. In: Newcastle Disease. edn. Edited by DJ A. Boston, Dordrecht, London: Kluwer Academic Publishers; 1998: 147-160.</text></passage><passage><infon key="fpage">2241</infon><infon key="issue">13</infon><infon key="lpage">2248</infon><infon key="name_0">surname:Yang;given-names:R</infon><infon key="name_1">surname:Pei;given-names:X</infon><infon key="name_2">surname:Wang;given-names:J</infon><infon key="name_3">surname:Zhang;given-names:Z</infon><infon key="name_4">surname:Zhao;given-names:H</infon><infon key="name_5">surname:Li;given-names:Q</infon><infon key="name_6">surname:Zhao;given-names:M</infon><infon key="name_7">surname:Li;given-names:Y</infon><infon key="pub-id_pmid">20632389</infon><infon key="section_type">REF</infon><infon key="source">J Sci Food Agric</infon><infon key="type">ref</infon><infon key="volume">90</infon><infon key="year">2010</infon><offset>42218</offset><text>Protective effect of a marine oligopeptide preparation from chum salmon (Oncorhynchus keta) on radiation-induced immune suppression in mice</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>42358</offset><text>Argmann CA, Auwerx J: Collection of blood and plasma from the mouse. Curr Protoc Mol Biol 2006, Chapter 29:Unit 29A 23.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>42478</offset><text>Abschuetz A, Kehl T, Geibig R: Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells. Cell and tissue ... 2006.</text></passage><passage><infon key="fpage">1164</infon><infon key="issue">7</infon><infon key="lpage">1172</infon><infon key="name_0">surname:Angelova;given-names:AL</infon><infon key="name_1">surname:Aprahamian;given-names:M</infon><infon key="name_2">surname:Balboni;given-names:G</infon><infon key="name_3">surname:Delecluse;given-names:H-J</infon><infon key="name_4">surname:Feederle;given-names:R</infon><infon key="name_5">surname:Kiprianova;given-names:I</infon><infon key="name_6">surname:Grekova;given-names:SP</infon><infon key="name_7">surname:Galabov;given-names:AS</infon><infon key="name_8">surname:Witzens-harig;given-names:M</infon><infon key="name_9">surname:Ho;given-names:AD</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2009</infon><offset>42681</offset><text>Oncolytic Rat Parvovirus H-1PV , a Candidate for the Treatment of Human Lymphoma : In Vitro and In Vivo Studies</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>42793</offset><text>Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12(1):103.</text></passage><passage><infon key="fpage">7522</infon><infon key="issue">15</infon><infon key="lpage">7534</infon><infon key="name_0">surname:Elankumaran;given-names:S</infon><infon key="name_1">surname:Rockemann;given-names:D</infon><infon key="name_2">surname:Samal;given-names:SK</infon><infon key="pub-id_pmid">16840332</infon><infon key="section_type">REF</infon><infon key="source">J Virol</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">2006</infon><offset>42942</offset><text>Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death</text></passage><passage><infon key="fpage">478</infon><infon key="lpage">482</infon><infon key="name_0">surname:Ahmed;given-names:I</infon><infon key="name_1">surname:Ahmad;given-names:U</infon><infon key="name_2">surname:Keong;given-names:Y</infon><infon key="name_3">surname:Manna;given-names:N</infon><infon key="name_4">surname:Othman;given-names:F</infon><infon key="section_type">REF</infon><infon key="source">J Cancer Sci Ther</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2014</infon><offset>43056</offset><text>Induction of Nitric Oxide and TNF-Alpha in Newcastle Disease Virus (NDV) AF2240 Infected RAW 264.7 Macrophages and their Cytotoxic Activity on MDA-MB-231 Breast Cancer Cell Line</text></passage><passage><infon key="fpage">279</infon><infon key="issue">2</infon><infon key="lpage">289</infon><infon key="name_0">surname:Hrabak;given-names:A</infon><infon key="name_1">surname:Csuka;given-names:I</infon><infon key="name_2">surname:Bajor;given-names:T</infon><infon key="name_3">surname:Csatary;given-names:LK</infon><infon key="pub-id_pmid">16399229</infon><infon key="section_type">REF</infon><infon key="source">Cancer Lett</infon><infon key="type">ref</infon><infon key="volume">231</infon><infon key="year">2006</infon><offset>43234</offset><text>The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro</text></passage><passage><infon key="fpage">2251</infon><infon key="issue">9</infon><infon key="lpage">2266</infon><infon key="name_0">surname:Pecora;given-names:AL</infon><infon key="name_1">surname:Rizvi;given-names:N</infon><infon key="name_10">surname:Roberts;given-names:MS</infon><infon key="name_11">surname:Rabin;given-names:H</infon><infon key="name_12">surname:Bamat;given-names:MK</infon><infon key="name_13">surname:Lorence;given-names:RM</infon><infon key="name_2">surname:Cohen;given-names:GI</infon><infon key="name_3">surname:Meropol;given-names:NJ</infon><infon key="name_4">surname:Sterman;given-names:D</infon><infon key="name_5">surname:Marshall;given-names:JL</infon><infon key="name_6">surname:Goldberg;given-names:S</infon><infon key="name_7">surname:Gross;given-names:P</infon><infon key="name_8">surname:O'Neil;given-names:JD</infon><infon key="name_9">surname:Groene;given-names:WS</infon><infon key="pub-id_pmid">11980996</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2002</infon><offset>43415</offset><text>Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers</text></passage><passage><infon key="fpage">221</infon><infon key="issue">1</infon><infon key="lpage">228</infon><infon key="name_0">surname:Freeman;given-names:AI</infon><infon key="name_1">surname:Zakay-Rones;given-names:Z</infon><infon key="name_10">surname:Galun;given-names:E</infon><infon key="name_11">surname:Siegal;given-names:T</infon><infon key="name_2">surname:Gomori;given-names:JM</infon><infon key="name_3">surname:Linetsky;given-names:E</infon><infon key="name_4">surname:Rasooly;given-names:L</infon><infon key="name_5">surname:Greenbaum;given-names:E</infon><infon key="name_6">surname:Rozenman-Yair;given-names:S</infon><infon key="name_7">surname:Panet;given-names:A</infon><infon key="name_8">surname:Libson;given-names:E</infon><infon key="name_9">surname:Irving;given-names:CS</infon><infon key="pub-id_pmid">16257582</infon><infon key="section_type">REF</infon><infon key="source">Mol Ther</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2006</infon><offset>43529</offset><text>Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme</text></passage><passage><infon key="fpage">27</infon><infon key="issue">1</infon><infon key="lpage">36</infon><infon key="name_0">surname:Phuangsab;given-names:A</infon><infon key="name_1">surname:Lorence;given-names:RM</infon><infon key="name_2">surname:Reichard;given-names:KW</infon><infon key="name_3">surname:Peeples;given-names:ME</infon><infon key="name_4">surname:Walter;given-names:RJ</infon><infon key="pub-id_pmid">11595126</infon><infon key="section_type">REF</infon><infon key="source">Cancer Lett</infon><infon key="type">ref</infon><infon key="volume">172</infon><infon key="year">2001</infon><offset>43622</offset><text>Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration</text></passage><passage><infon key="fpage">3</infon><infon key="issue">1</infon><infon key="lpage">10</infon><infon key="name_0">surname:Zulkifli;given-names:MM</infon><infon key="name_1">surname:Ibrahim;given-names:R</infon><infon key="name_2">surname:Ali;given-names:AM</infon><infon key="name_3">surname:Aini;given-names:I</infon><infon key="name_4">surname:Jaafar;given-names:H</infon><infon key="name_5">surname:Hilda;given-names:SS</infon><infon key="name_6">surname:Alitheen;given-names:NB</infon><infon key="name_7">surname:Abdullah;given-names:JM</infon><infon key="pub-id_pmid">18937888</infon><infon key="section_type">REF</infon><infon key="source">Neurol Res</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2009</infon><offset>43735</offset><text>Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma</text></passage><passage><infon key="fpage">8645</infon><infon key="issue">2011</infon><infon key="lpage">8660</infon><infon key="name_0">surname:Alabsi;given-names:AM</infon><infon key="name_1">surname:Bakar;given-names:SAA</infon><infon key="name_2">surname:Ali;given-names:R</infon><infon key="name_3">surname:Omar;given-names:AR</infon><infon key="name_4">surname:Bejo;given-names:MH</infon><infon key="name_5">surname:Ideris;given-names:A</infon><infon key="name_6">surname:Ali;given-names:AM</infon><infon key="pub-id_pmid">22272097</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2011</infon><offset>43845</offset><text>Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>43956</offset><text>Ahmad U, Ahmed I, Keong YY, Abd Manan N, Othman F. Inhibitory and apoptosis-inducing effects of newcastle disease virus strain AF2240 on mammary carcinoma cell line. Biomed Res Int. 2015;2015.</text></passage><passage><infon key="fpage">656</infon><infon key="issue">3</infon><infon key="lpage">661</infon><infon key="name_0">surname:Harvie;given-names:M</infon><infon key="name_1">surname:Howell;given-names:A</infon><infon key="name_2">surname:Vierkant;given-names:RA</infon><infon key="name_3">surname:Kumar;given-names:N</infon><infon key="name_4">surname:Cerhan;given-names:JR</infon><infon key="name_5">surname:Kelemen;given-names:LE</infon><infon key="name_6">surname:Folsom;given-names:AR</infon><infon key="name_7">surname:Sellers;given-names:TA</infon><infon key="section_type">REF</infon><infon key="source">Cancer Epidemiol Biomark Prev</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2005</infon><offset>44149</offset><text>Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study</text></passage><passage><infon key="fpage">1128</infon><infon key="issue">4</infon><infon key="lpage">1143</infon><infon key="name_0">surname:Chlebowski;given-names:RT</infon><infon key="name_1">surname:Aiello;given-names:E</infon><infon key="name_2">surname:McTiernan;given-names:A</infon><infon key="pub-id_pmid">11844838</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2002</infon><offset>44290</offset><text>Weight loss in breast cancer patient management</text></passage><passage><infon key="fpage">17</infon><infon key="name_0">surname:Gowda;given-names:S</infon><infon key="name_1">surname:Desai;given-names:PB</infon><infon key="name_2">surname:Hull;given-names:VV</infon><infon key="name_3">surname:Math;given-names:AA</infon><infon key="name_4">surname:Vernekar;given-names:SN</infon><infon key="name_5">surname:Kulkarni;given-names:SS</infon><infon key="pub-id_pmid">21532726</infon><infon key="section_type">REF</infon><infon key="source">Pan Afr Med J</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2009</infon><offset>44338</offset><text>A review on laboratory liver function tests</text></passage><passage><infon key="fpage">243</infon><infon key="issue">5</infon><infon key="lpage">249</infon><infon key="name_0">surname:Rahman;given-names:MF</infon><infon key="name_1">surname:Siddiqui;given-names:MK</infon><infon key="name_2">surname:Jamil;given-names:K</infon><infon key="pub-id_pmid">11476156</infon><infon key="section_type">REF</infon><infon key="source">Hum Exp Toxicol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2001</infon><offset>44382</offset><text>Effects of Vepacide (Azadirachta indica) on aspartate and alanine aminotransferase profiles in a subchronic study with rats</text></passage><passage><infon key="fpage">109</infon><infon key="issue">2-3</infon><infon key="lpage">118</infon><infon key="name_0">surname:Parvez;given-names:S</infon><infon key="name_1">surname:Tabassum;given-names:H</infon><infon key="name_2">surname:Rehman;given-names:H</infon><infon key="name_3">surname:Banerjee;given-names:BD</infon><infon key="name_4">surname:Athar;given-names:M</infon><infon key="name_5">surname:Raisuddin;given-names:S</infon><infon key="pub-id_pmid">16797820</infon><infon key="section_type">REF</infon><infon key="source">Toxicology</infon><infon key="type">ref</infon><infon key="volume">225</infon><infon key="year">2006</infon><offset>44506</offset><text>Catechin prevents tamoxifen-induced oxidative stress and biochemical perturbations in mice</text></passage><passage><infon key="fpage">593</infon><infon key="issue">6</infon><infon key="lpage">598</infon><infon key="name_0">surname:Elefsiniotis;given-names:ISPK</infon><infon key="name_1">surname:Ilias;given-names:A</infon><infon key="name_2">surname:Pallis;given-names:L</infon><infon key="name_3">surname:Mariolis;given-names:A</infon><infon key="name_4">surname:Glynou;given-names:I</infon><infon key="name_5">surname:Kada;given-names:H</infon><infon key="name_6">surname:Moulakakis;given-names:A</infon><infon key="pub-id_pmid">15167162</infon><infon key="section_type">REF</infon><infon key="source">Eur J Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2004</infon><offset>44597</offset><text>Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance</text></passage><passage><infon key="fpage">840</infon><infon key="issue">7</infon><infon key="lpage">845</infon><infon key="name_0">surname:Nyblom;given-names:H</infon><infon key="name_1">surname:Bjornsson;given-names:E</infon><infon key="name_2">surname:Simren;given-names:M</infon><infon key="name_3">surname:Aldenborg;given-names:F</infon><infon key="name_4">surname:Almer;given-names:S</infon><infon key="name_5">surname:Olsson;given-names:R</infon><infon key="pub-id_pmid">16911467</infon><infon key="section_type">REF</infon><infon key="source">Liver Int</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2006</infon><offset>44723</offset><text>The AST/ALT ratio as an indicator of cirrhosis in patients with PBC</text></passage><passage><infon key="fpage">1227</infon><infon key="issue">15</infon><infon key="lpage">1232</infon><infon key="name_0">surname:Huang;given-names:SS</infon><infon key="name_1">surname:Huang;given-names:PH</infon><infon key="name_2">surname:Leu;given-names:HB</infon><infon key="name_3">surname:Wu;given-names:TC</infon><infon key="name_4">surname:Lin;given-names:SJ</infon><infon key="name_5">surname:Chen;given-names:JW</infon><infon key="pub-id_pmid">20639239</infon><infon key="section_type">REF</infon><infon key="source">Heart</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">2010</infon><offset>44791</offset><text>Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome X</text></passage><passage><infon key="fpage">292</infon><infon key="issue">3</infon><infon key="lpage">296</infon><infon key="name_0">surname:Rios;given-names:DL</infon><infon key="name_1">surname:Cerqueira;given-names:CC</infon><infon key="name_2">surname:Bonfim-Silva;given-names:R</infon><infon key="name_3">surname:Araujo;given-names:LJ</infon><infon key="name_4">surname:Pereira;given-names:JF</infon><infon key="name_5">surname:Gadelha;given-names:SR</infon><infon key="name_6">surname:Barbosa;given-names:AA</infon><infon key="pub-id_pmid">20206549</infon><infon key="section_type">REF</infon><infon key="source">Cytokine</infon><infon key="type">ref</infon><infon key="volume">50</infon><infon key="year">2010</infon><offset>44880</offset><text>Interleukin-1 beta and interleukin-6 gene polymorphism associations with angiographically assessed coronary artery disease in Brazilians</text></passage><passage><infon key="fpage">451</infon><infon key="issue">6</infon><infon key="lpage">461</infon><infon key="name_0">surname:Mitsuyama;given-names:K</infon><infon key="name_1">surname:Sata;given-names:M</infon><infon key="name_2">surname:Rose-John;given-names:S</infon><infon key="pub-id_pmid">17045835</infon><infon key="section_type">REF</infon><infon key="source">Cytokine Growth Factor Rev</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2006</infon><offset>45017</offset><text>Interleukin-6 trans-signaling in inflammatory bowel disease</text></passage><passage><infon key="fpage">99</infon><infon key="issue">2</infon><infon key="lpage">102</infon><infon key="name_0">surname:Zhang;given-names:Y</infon><infon key="name_1">surname:Hayes;given-names:A</infon><infon key="name_10">surname:St Clair;given-names:D</infon><infon key="name_11">surname:Iwatsubo;given-names:T</infon><infon key="name_12">surname:Mann;given-names:DM</infon><infon key="name_13">surname:Lendon;given-names:CL</infon><infon key="name_2">surname:Pritchard;given-names:A</infon><infon key="name_3">surname:Thaker;given-names:U</infon><infon key="name_4">surname:Haque;given-names:MS</infon><infon key="name_5">surname:Lemmon;given-names:H</infon><infon key="name_6">surname:Harris;given-names:J</infon><infon key="name_7">surname:Cumming;given-names:A</infon><infon key="name_8">surname:Lambert;given-names:JC</infon><infon key="name_9">surname:Chartier-Harlin;given-names:MC</infon><infon key="pub-id_pmid">15193763</infon><infon key="section_type">REF</infon><infon key="source">Neurosci Lett</infon><infon key="type">ref</infon><infon key="volume">362</infon><infon key="year">2004</infon><offset>45077</offset><text>Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease</text></passage><passage><infon key="fpage">76</infon><infon key="issue">1</infon><infon key="lpage">78</infon><infon key="name_0">surname:Esfandi;given-names:F</infon><infon key="name_1">surname:Ghobadloo;given-names:SM</infon><infon key="name_2">surname:Basati;given-names:G</infon><infon key="pub-id_pmid">16442710</infon><infon key="section_type">REF</infon><infon key="source">Cancer Lett</infon><infon key="type">ref</infon><infon key="volume">244</infon><infon key="year">2006</infon><offset>45156</offset><text>Interleukin-6 level in patients with colorectal cancer</text></passage><passage><infon key="fpage">405</infon><infon key="issue">4</infon><infon key="lpage">409</infon><infon key="name_0">surname:Dowlati;given-names:A</infon><infon key="name_1">surname:Levitan;given-names:N</infon><infon key="name_2">surname:Remick;given-names:SC</infon><infon key="pub-id_pmid">10521088</infon><infon key="section_type">REF</infon><infon key="source">J Lab Clin Med</infon><infon key="type">ref</infon><infon key="volume">134</infon><infon key="year">1999</infon><offset>45211</offset><text>Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer</text></passage><passage><infon key="fpage">1242</infon><infon key="issue">6</infon><infon key="lpage">1247</infon><infon key="name_0">surname:Soygur;given-names:H</infon><infon key="name_1">surname:Palaoglu;given-names:O</infon><infon key="name_2">surname:Akarsu;given-names:ES</infon><infon key="name_3">surname:Cankurtaran;given-names:ES</infon><infon key="name_4">surname:Ozalp;given-names:E</infon><infon key="name_5">surname:Turhan;given-names:L</infon><infon key="name_6">surname:Ayhan;given-names:IH</infon><infon key="section_type">REF</infon><infon key="source">Prog Neuro-Psychopharmacol Biol Psychiatry</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2007</infon><offset>45310</offset><text>Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder</text></passage><passage><infon key="fpage">188</infon><infon key="issue">2</infon><infon key="lpage">194</infon><infon key="name_0">surname:Hodge;given-names:DR</infon><infon key="name_1">surname:Xiao;given-names:W</infon><infon key="name_2">surname:Wang;given-names:LH</infon><infon key="name_3">surname:Li;given-names:D</infon><infon key="name_4">surname:Farrar;given-names:WL</infon><infon key="pub-id_pmid">14726660</infon><infon key="section_type">REF</infon><infon key="source">Cancer Biol Ther</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2004</infon><offset>45412</offset><text>Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells</text></passage><passage><infon key="fpage">5991</infon><infon key="issue">42</infon><infon key="lpage">6000</infon><infon key="name_0">surname:Hideshima;given-names:T</infon><infon key="name_1">surname:Nakamura;given-names:N</infon><infon key="name_2">surname:Chauhan;given-names:D</infon><infon key="name_3">surname:Anderson;given-names:KC</infon><infon key="pub-id_pmid">11593406</infon><infon key="section_type">REF</infon><infon key="source">Oncogene</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2001</infon><offset>45548</offset><text>Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma</text></passage><passage><infon key="fpage">1305</infon><infon key="issue">16</infon><infon key="lpage">1312</infon><infon key="name_0">surname:Lorence;given-names:RM</infon><infon key="name_1">surname:Rood;given-names:PA</infon><infon key="name_2">surname:Kelley;given-names:KW</infon><infon key="pub-id_pmid">2459402</infon><infon key="section_type">REF</infon><infon key="source">J Natl Cancer Inst</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">1988</infon><offset>45631</offset><text>Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor-alpha and Augmentation of Its Cytotoxicity</text></passage><passage><infon key="fpage">213</infon><infon key="issue">3</infon><infon key="lpage">217</infon><infon key="name_0">surname:Rood;given-names:PA</infon><infon key="name_1">surname:Lorence;given-names:RM</infon><infon key="name_2">surname:Kelley;given-names:KW</infon><infon key="pub-id_pmid">2296051</infon><infon key="section_type">REF</infon><infon key="source">J Natl Cancer Inst</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">1990</infon><offset>45761</offset><text>Serum Protease Inhibitor Abrogation of Newcastle Disease Virus Enhancement of Cytolysis by Recombinant Tumor Necrosis Factors Alpha and Beta</text></passage><passage><infon key="fpage">1814</infon><infon key="issue">4</infon><infon key="lpage">1821</infon><infon key="name_0">surname:Washburn;given-names:B</infon><infon key="name_1">surname:Weigand;given-names:MA</infon><infon key="name_2">surname:Grosse-Wilde;given-names:A</infon><infon key="name_3">surname:Janke;given-names:M</infon><infon key="name_4">surname:Stahl;given-names:H</infon><infon key="name_5">surname:Rieser;given-names:E</infon><infon key="name_6">surname:Sprick;given-names:MR</infon><infon key="name_7">surname:Schirrmacher;given-names:V</infon><infon key="name_8">surname:Walczak;given-names:H</infon><infon key="pub-id_pmid">12574346</infon><infon key="section_type">REF</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="volume">170</infon><infon key="year">2003</infon><offset>45902</offset><text>TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus</text></passage><passage><infon key="fpage">429</infon><infon key="issue">7</infon><infon key="lpage">437</infon><infon key="name_0">surname:Eggermont;given-names:AM</infon><infon key="name_1">surname:de Wilt;given-names:JH</infon><infon key="name_2">surname:ten Hagen;given-names:TL</infon><infon key="pub-id_pmid">12850194</infon><infon key="section_type">REF</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2003</infon><offset>46027</offset><text>Current uses of isolated limb perfusion in the clinic and a model system for new strategies</text></passage><passage><infon key="fpage">3877</infon><infon key="issue">9</infon><infon key="lpage">3882</infon><infon key="name_0">surname:Sgadari;given-names:C</infon><infon key="name_1">surname:Angiolillo;given-names:AL</infon><infon key="name_2">surname:Tosato;given-names:G</infon><infon key="pub-id_pmid">8611715</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">87</infon><infon key="year">1996</infon><offset>46119</offset><text>Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10</text></passage><passage><infon key="fpage">151</infon><infon key="issue">1</infon><infon key="lpage">157</infon><infon key="name_0">surname:Dias;given-names:S</infon><infon key="name_1">surname:Thomas;given-names:H</infon><infon key="name_2">surname:Balkwill;given-names:F</infon><infon key="pub-id_pmid">9426704</infon><infon key="section_type">REF</infon><infon key="source">Int J Cancer</infon><infon key="type">ref</infon><infon key="volume">75</infon><infon key="year">1998</infon><offset>46215</offset><text>Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model</text></passage><passage><infon key="fpage">1697</infon><infon key="issue">4</infon><infon key="lpage">1706</infon><infon key="name_0">surname:HD;given-names:NCLE</infon><infon key="name_1">surname:McKinney;given-names:TG</infon><infon key="name_2">surname:Tahara;given-names:H</infon><infon key="name_3">surname:Nalesnik;given-names:MA</infon><infon key="name_4">surname:Brunda;given-names:MJ</infon><infon key="name_5">surname:Gately;given-names:MK</infon><infon key="name_6">surname:Wolf;given-names:SF</infon><infon key="name_7">surname:Schreiber;given-names:RD</infon><infon key="name_8">surname:Storkus;given-names:WJ</infon><infon key="pub-id_pmid">7913943</infon><infon key="section_type">REF</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="volume">153</infon><infon key="year">1994</infon><offset>46353</offset><text>Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production</text></passage><passage><infon key="name_0">surname:Elgert;given-names:KD</infon><infon key="section_type">REF</infon><infon key="source">Immunology: Understanding the immune system</infon><infon key="type">ref</infon><infon key="year">2009</infon><offset>46452</offset></passage><passage><infon key="fpage">630</infon><infon key="issue">4</infon><infon key="lpage">637</infon><infon key="name_0">surname:Yue;given-names:FY</infon><infon key="name_1">surname:Dummer;given-names:R</infon><infon key="name_2">surname:Geertsen;given-names:R</infon><infon key="name_3">surname:Hofbauer;given-names:G</infon><infon key="name_4">surname:Laine;given-names:E</infon><infon key="name_5">surname:Manolio;given-names:S</infon><infon key="name_6">surname:Burg;given-names:G</infon><infon key="pub-id_pmid">9178819</infon><infon key="section_type">REF</infon><infon key="source">Int J Cancer</infon><infon key="type">ref</infon><infon key="volume">71</infon><infon key="year">1997</infon><offset>46453</offset><text>Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules</text></passage><passage><infon key="fpage">25</infon><infon key="issue">1</infon><infon key="lpage">32</infon><infon key="name_0">surname:Piancatelli;given-names:D</infon><infon key="name_1">surname:Romano;given-names:P</infon><infon key="name_2">surname:Sebastiani;given-names:P</infon><infon key="name_3">surname:Adorno;given-names:D</infon><infon key="name_4">surname:Casciani;given-names:CU</infon><infon key="pub-id_pmid">9924696</infon><infon key="section_type">REF</infon><infon key="source">J Immunother</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">1999</infon><offset>46578</offset><text>Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression</text></passage><passage><infon key="fpage">683</infon><infon key="lpage">765</infon><infon key="name_0">surname:Moore;given-names:KW</infon><infon key="name_1">surname:de Waal Malefyt;given-names:R</infon><infon key="name_2">surname:Coffman;given-names:RL</infon><infon key="name_3">surname:O'Garra;given-names:A</infon><infon key="pub-id_pmid">11244051</infon><infon key="section_type">REF</infon><infon key="source">Annu Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2001</infon><offset>46690</offset><text>Interleukin-10 and the interleukin-10 receptor</text></passage><passage><infon key="fpage">1287</infon><infon key="issue">5</infon><infon key="lpage">1292</infon><infon key="name_0">surname:Hatanaka;given-names:H</infon><infon key="name_1">surname:Abe;given-names:Y</infon><infon key="name_10">surname:Kijima;given-names:H</infon><infon key="name_11">surname:Yamazaki;given-names:H</infon><infon key="name_12">surname:Inoue;given-names:H</infon><infon key="name_13">surname:Ueyama;given-names:Y</infon><infon key="name_14">surname:Nakamura;given-names:M</infon><infon key="name_2">surname:Naruke;given-names:M</infon><infon key="name_3">surname:Tokunaga;given-names:T</infon><infon key="name_4">surname:Oshika;given-names:Y</infon><infon key="name_5">surname:Kawakami;given-names:T</infon><infon key="name_6">surname:Osada;given-names:H</infon><infon key="name_7">surname:Nagata;given-names:J</infon><infon key="name_8">surname:Kamochi;given-names:J</infon><infon key="name_9">surname:Tsuchida;given-names:T</infon><infon key="pub-id_pmid">11350896</infon><infon key="section_type">REF</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2001</infon><offset>46737</offset><text>Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in non-small cell lung cancer</text></passage><passage><infon key="fpage">701</infon><infon key="issue">3</infon><infon key="lpage">705</infon><infon key="name_0">surname:Gerger;given-names:A</infon><infon key="name_1">surname:Renner;given-names:W</infon><infon key="name_2">surname:Langsenlehner;given-names:T</infon><infon key="name_3">surname:Hofmann;given-names:G</infon><infon key="name_4">surname:Knechtel;given-names:G</infon><infon key="name_5">surname:Szkandera;given-names:J</infon><infon key="name_6">surname:Samonigg;given-names:H</infon><infon key="name_7">surname:Krippl;given-names:P</infon><infon key="name_8">surname:Langsenlehner;given-names:U</infon><infon key="pub-id_pmid">19437115</infon><infon key="section_type">REF</infon><infon key="source">Breast Cancer Res Treat</infon><infon key="type">ref</infon><infon key="volume">119</infon><infon key="year">2010</infon><offset>46880</offset><text>Association of interleukin-10 gene variation with breast cancer prognosis</text></passage><passage><infon key="fpage">82</infon><infon key="lpage">84</infon><infon key="name_0">surname:Kozlowski;given-names:L</infon><infon key="name_1">surname:Zakrzewska;given-names:I</infon><infon key="name_2">surname:Tokajuk;given-names:P</infon><infon key="name_3">surname:Wojtukiewicz;given-names:MZ</infon><infon key="pub-id_pmid">14737948</infon><infon key="section_type">REF</infon><infon key="source">Rocz Akad Med Bialymst</infon><infon key="type">ref</infon><infon key="volume">48</infon><infon key="year">2003</infon><offset>46954</offset><text>Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients</text></passage><passage><infon key="fpage">116</infon><infon key="issue">2</infon><infon key="lpage">122</infon><infon key="name_0">surname:Razmkhah;given-names:M</infon><infon key="name_1">surname:Jaberipour;given-names:M</infon><infon key="name_2">surname:Erfani;given-names:N</infon><infon key="name_3">surname:Habibagahi;given-names:M</infon><infon key="name_4">surname:Talei;given-names:AR</infon><infon key="name_5">surname:Ghaderi;given-names:A</infon><infon key="pub-id_pmid">20970781</infon><infon key="section_type">REF</infon><infon key="source">Cell Immunol</infon><infon key="type">ref</infon><infon key="volume">266</infon><infon key="year">2011</infon><offset>47082</offset><text>Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-beta1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response?</text></passage><passage><infon key="fpage">1287</infon><infon key="issue">3</infon><infon key="lpage">1293</infon><infon key="name_0">surname:Toi;given-names:M</infon><infon key="name_1">surname:Harris;given-names:AL</infon><infon key="name_2">surname:Bicknell;given-names:R</infon><infon key="pub-id_pmid">1996992</infon><infon key="section_type">REF</infon><infon key="source">Biochem Biophys Res Commun</infon><infon key="type">ref</infon><infon key="volume">174</infon><infon key="year">1991</infon><offset>47309</offset><text>Interleukin-4 is a potent mitogen for capillary endothelium</text></passage><passage><infon key="fpage">3282</infon><infon key="issue">8</infon><infon key="lpage">3289</infon><infon key="name_0">surname:Ueno;given-names:T</infon><infon key="name_1">surname:Toi;given-names:M</infon><infon key="name_2">surname:Saji;given-names:H</infon><infon key="name_3">surname:Muta;given-names:M</infon><infon key="name_4">surname:Bando;given-names:H</infon><infon key="name_5">surname:Kuroi;given-names:K</infon><infon key="name_6">surname:Koike;given-names:M</infon><infon key="name_7">surname:Inadera;given-names:H</infon><infon key="name_8">surname:Matsushima;given-names:K</infon><infon key="pub-id_pmid">10955814</infon><infon key="section_type">REF</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2000</infon><offset>47369</offset><text>Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer</text></passage><passage><infon key="fpage">14</infon><infon key="issue">1-2</infon><infon key="lpage">17</infon><infon key="name_0">surname:Lebrecht;given-names:A</infon><infon key="name_1">surname:Grimm;given-names:C</infon><infon key="name_2">surname:Lantzsch;given-names:T</infon><infon key="name_3">surname:Ludwig;given-names:E</infon><infon key="name_4">surname:Hefler;given-names:L</infon><infon key="name_5">surname:Ulbrich;given-names:E</infon><infon key="name_6">surname:Koelbl;given-names:H</infon><infon key="pub-id_pmid">15192307</infon><infon key="section_type">REF</infon><infon key="source">Tumour Biol</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2004</infon><offset>47499</offset><text>Monocyte chemoattractant protein-1 serum levels in patients with breast cancer</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>47578</offset><text>Conti P, DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc. t2001;22(3):133-7.</text></passage></document>
</collection>